



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N</b>	<b>A2</b>	(11) International Publication Number: <b>WO 00/12677</b>
		(43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/IB99/01604 (22) International Filing Date: 1 September 1999 (01.09.99) (30) Priority Data: 60/098,684 1 September 1998 (01.09.98) US (71) Applicant: THE UNIVERSITY OF HONG KONG [CN/CN]; G18, Eliot Hall, Pokfulam Road, Hong Kong (CN). (72) Inventor: LIM, Boon-Leong; Tower I, 39th floor, Flat E, Kornville Garden, 38 Yau Man Street, Hong Kong (CN). (74) Agent: CHINA PATENT AGENT (H.K.) LTD.; 22/F, Great Eagle Centre, 23 Harbour Road, Wanchai, Special Admin- istrative Region Hong Kong (CN).		(81) Designated States: European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished          upon receipt of that report.</i>

(54) Title: GENERATION OF RECOMBINANT INFECTIOUS BURSAL DISEASE VIRUSES BY REVERSE GENETICS TECHNOLOGY AND THE USE OF THE RECOMBINANT VIRUSES AS ATTENUATED VACCINES

143		222
HK46	.....	.....A
UK661	.....	.....A
G9201	.....	.....A
F9502	.....	A.....A
G9303	.....A.....	V.....A.....A
52/70	.....	.....
STC	.....	.....
CJ801	.....S.....	.....L.....T
Variant-A	.....	.....Q
Variant-E	.....	N.....T
GZ902	.....	.....Q
GLS	.....	.....T
CJ8018KF	.....	.....
CU-1	.....	.....
PBG-98	.....	.....
GZ911	.....	.....
002-73	.....	G.....
Consensus	GLMSATANIN DKIGNVLVE GVTVLSLPTS YDLGYRLGD PIPAIGLOPK MWATCOSSOR PRVYTITAA	D DYQFSSQYQP

## (57) Abstract

The invention relates to the generation and mutagenesis of recombinant infectious bursal disease virus by reverse genetics technology. Site-directed mutagenesis of certain amino acid residues on the Non-CEF adapted, very virulent strains of IBDV transforms the viruses into attenuated, CEF-adapted strains. The attenuated, CEF-adapted strains can be used as live vaccines against the very virulent strains. Currently available live attenuated vaccines were generated by serial passage through cell culture and the like, whereas the present invention provides a novel molecular mechanism in manipulation of the viral genome and the generation of attenuated vaccines by site-directed mutagenesis. The same approach can be used to produce vaccine strains from newly evolved IBDV viruses or to manipulate the antigenicity and pathogenicity of the virus.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GENERATION OF RECOMBINANT INFECTIOUS BURSAL DISEASE  
VIRUSES BY REVERSE GENETICS TECHNOLOGY AND THE USE OF  
THE RECOMBINANT VIRUSES AS ATTENUATED VACCINES

5

RELATED APPLICATION

This application claims the priority of provisional patent application no. 60/098,684, filed on September 1, 1998.

FIELD OF THE INVENTION

10 This invention is in the field of molecular biology. This invention relates to the generation of recombinant infectious bursal disease virus and the manipulation of the viral genome by the reverse genetics technology. In particular, it relates to two DNA molecules comprising artificially constructed polynucleotide sequences substantially corresponding to all or a portion of infectious bursal disease d.s. RNA  
15 genome and the mutagenesis of certain amino acid residues of the virus so as to generate mutated attenuated vaccine strains against the virus.

BACKGROUND OF INVENTION

Infectious bursal disease (IBD), caused by infectious bursal disease virus  
20 (IBDV), is a highly contagious disease of young chickens, which results in significant losses to the poultry industry. After infection, IBDV multiplies rapidly in the developing B lymphocytes of the bursa of Fabricius, leading to immunosuppression and increased susceptibility to other diseases. Two distinct serotypes of IBDV, designated as serotype 1 and serotype 2, have been identified. The serotype 1  
25 strains are pathogenic to chicken and vary in their virulence, whereas serotype 2 strains isolated from turkey, are apathogenic for both turkey and chicken. According to antigenic variation and virulence, serotype 1 strains can be divided into several groups: classical virulent strains, attenuated strains, antigenic variant strains and very virulent (vv) strains. Classical virulent strains cause bursal inflammation and  
30 severe lymphoid necrosis in infected chicken, resulting in immunodeficiency and moderate mortality. Generally, mortality peaks by the third day post-infection but death may still occur over the next 5 to 7 days resulting in a mortality up to 20%~30% in specific pathogen free (SPF) chickens. Attenuated strains have been adapted to chick embryo fibroblast (CEF) cells or other cell lines. They do not cause  
35 diseases in chickens, and therefore some of them are being used as live vaccines.

Antigenic variant strains were recognized by their ability to escape cross-neutralization by the antisera against classical strains. Chickens affected by the variant strains are characterized by severe atrophy of the bursa, without showing the inflammation symptom associated with the infection of classical strains

5 (Vakharia et al. *Virus Res* 31:265-273, (1994)). Since the late eighties, the outbreaks of newly evolved, very virulent (vv) strains in Europe, Japan and China cause significant economical losses to the poultry industry. The vv strains can cause up to 60-100% mortality in SPF birds. These vv strains cause typical lesions of IBDV and are antigenically similar to the classical strains (Cao, Y. et al, *Avian Dis.* 42,

10 340-351, (1998)).

— IBDV is a member of the Birnaviridae family, as its genome consists of two segments of double-stranded RNA (dsRNA). The smaller RNA segment (segment B) with a length of about 2.8kb, encodes VP1, a 90 kDa multifunctional protein with polymerase and capping enzyme activities. The larger RNA segment (segment A),

15 with a length of about 3.2kb, encodes a polyprotein that is cleaved by autoproteolysis to form mature viral proteins VP2, VP3 and VP4. VP2 and VP3 are the major structural proteins of the virion, of which VP2 is the major host-protective immunogen of IBDV that contains the antigenic regions responsible for the induction of neutralizing antibodies (Brown, M. D. and Skinner, M. A. *Virus Res*,

20 40:1-15, (1996)). A second open reading frame (ORF), preceding and partially overlapping the polyprotein gene, encodes VP5, a 17kD polypeptide present in IBDV-infected cells. However, the function of the polypeptide is still unknown. The nucleotide sequences of genome segments A and B of various IBDV strains have been published, which conclude that the sequences of the major host-protective

25 immunogen VP2 are highly conserved, except the central *AccI*-*SpeI* restriction fragment which has been designated as the hypervariable region.

Seven infectious bursal disease virus strains isolated from China have recently been characterized (Cao, Y. et al, *Avian Dis.* 42, 340-351, (1998)), including a classical strain CJ801, an attenuated strain GZ911, a variant strain

30 GZ902, and four very virulent strains G9201, G9302, F9502 and HK46. Using reverse transcription-polymerase chain reaction (RT-PCR), the full length VP2 genes were amplified and the hypervariable regions were sequenced. Protein sequences of the hypervariable region (a.a. 143-382) of the field isolates confirmed their identities (Figure 1). CJ801 has the highest identity to the classical strains STC and

35 52/70. GZ902 has the highest identity to the American variant strains A, E and GLS

and they share unique amino acid residue at position 249K and 254S, which are not present in the other serotype 1 strains. Attenuated strain GZ911, like other cell culture-adapted strains, has substitutions at positions 279(D to N) and 284(A to T) as well as in the serine-rich heptapeptide region. Hence, these substitutions may

5 play important roles in the reduced virulence of these strains. The four very virulent strains have the highest identity to the European very virulent strain UK661 and Japanese strain OKYM. They share unique amino acid residues at positions 222A, 256I, 294I, and 299S which are not present in other less virulent strains. The very virulent strains isolated in Guangdong (G9201, G9303) and Fujian (F9502)

10 provinces have 1 to 5 amino acid substitutions at the two hydrophilic domains of VP2 comparing to UK661 and OKYM, indicating that new very virulent strains are evolving. Phylogenetic analysis suggests that Chinese very virulent IBDVs and European very virulent strains are derived from similar origin (Figure 2).

The principal methods of controlling IBD in young chickens are by

15 vaccination with live attenuated strain of IBDV at the age of 0-5 weeks, or by in ovo vaccination, or by transferring high levels of maternal antibody induced by the administration of live and killed IBD vaccines to the breeder hens (Wyeth and Cullen, 1979). Both live attenuated virus vaccine and inactivated virus vaccine for this disease are available on the markets. The live attenuated vaccine available on

20 the markets are generally derived by serial passage of classical or variant strains in embryonated SPF eggs, or in cells derived from embryonated SPF eggs, such as primary or secondary chicken embryo fibroblasts (CEF). Only the strains with their virulence reduced or eliminated by these methods can be used as live attenuated vaccines. Inactivated vaccine is prepared by culturing the virus itself, or by

25 propagating the virus in SPF chicken, which are subsequently inactivated by heat, chemical treatment and the like. The attenuated strains derived from the classical strains and the variant strains can usually protect the birds from the attacks of the classical strains and the variant strains, respectively. However, these vaccine strains do not always offer 100% protection against the very virulent strains discovered in

30 the recent years. Hence, it is important to develop an attenuated vaccine strains from the very virulent strains.

#### SUMMARY OF INVENTION

In general, attenuated live virus vaccines are preferred because they provoke

35 a more long-lasting immune response (often both humoral and cellular), a good

mucosal immunity and are easy to produce. Presently live infectious bursal disease vaccines are developed by multiple passages of the field virus in chicken embryonic fibroblasts or in embryonated eggs. Hence, the method of producing live attenuated virus is a random, uncontrolled process and as a result, these vaccines suffer from a  
5 number of drawbacks. Firstly, a field virus may not be adapted to CEF after many attempts and hence no live attenuated virus could be derived. Secondly, even some of the field viruses can be adapted in CEF, a population of viruses of different characteristics and different degree of virulence may be generated. Because uncontrolled mutations are introduced into the viral genome during serial passages,  
10 a population of virus particles heterogeneous in their virulence and immunizing properties are generated. Single virus has to be cloned and the pathogenicity of each cloned virus has to be tested. Thirdly, it is possible that such traditional attenuated live virus vaccines can revert to virulence, resulting in disease of the inoculated animals and the possible spread of the pathogen to other animals.

15 In this invention, the development of techniques for controlled manipulation of genetic material has allowed the creation of CEF-adapted virus vaccines which avoids the disadvantages of the attenuated virus vaccines generated by conventional techniques.

The present invention involves the generation of full length cDNA from the  
20 double strand RNA genome of the a very virulent IBDV strain by reverse transcription. The two cDNAs were individually cloned into eukaryotic expression vectors before carrying out site-directed mutagenesis. The transfection of the mutated expression vectors into chicken embryo fibroblasts allowed the regeneration of a CEF adapted, live virus, whereas the transfection of the non-  
25 mutated expression vectors could not generate any live virus.

The present invention provide a novel technique that creates CEF-adapted IBDV strains by site-directed mutagenesis which can be used for the preparation of live and inactivated vaccines against IBDV infection. The mutant viruses being attenuated in a controlled manner can elicits a strong immune response in host  
30 animals.

It is another object of the present invention to create new live vaccine strains from classical, variant, very virulent or any other newly evolved IBDV strains.

It is another object of the present invention to provide a mutant IBDV which can be used not only for the preparation of a vaccine against IBDV infection but also  
35 against other infectious diseases.

It is a further object of the present invention to produce subunit vaccines, pharmaceutical and diagnostic preparations comprising a heterologous polypeptide expressed by an IBDV mutant according to the invention.

5

#### BRIEF DESCRIPTION OF THE DRAWINGS

These and other objects, features and elements of the present invention will be better understood from the following detailed description of preferred embodiments of the invention in which:

Fig. 1 shows an alignment of the hypervariable regions of various ISDV  
10 strains.

Fig. 2 shows the phylogenetic tree showing the relationship between various IBDV strains.

Fig. 3 shows construction of plasmid FA-pBssK containing full-length cDNA copy of segment

15 Fig. 4 shows construction of plasmid FB-pBssK containing full-length cDNA copy of segment B of IBDV HK46 strain.

Fig. 5 shows changes in Bursa Weight after virus inoculation.

#### DETAILED DESCRIPTION

20 From a previous publication of our group (Cao, Y. et al, Avian Dis. 42, 340-351, (1998)), the hypervariable region of the VP2 protein of seven Chinese IBDV strains were characterized. By comparing the sequences (Fig.1), several amino acid residues on the VP2 protein were postulated to be responsible for the attenuation of the virus or the antigenicity of the virus. Based on these data, this invention  
25 developed a molecular procedure that can be used to engineering IBDV genome in a controlled manner, which can change the property of the virus, such as generating a live attenuated strain of specific antigenicity.

The invention comprises of the RNA genomes derived from a very virulent IBDV strain HK46, including a biological pure RNA encoding SEQ ID NO:1, which  
30 encodes a 1012 amino acids long polypeptide, and a biological pure RNA encoding SEQ ID NO:2, which encode a polypeptide of 879 amino acids long. The RNA genomes were reverse transcribed into cDNAs which were then subcloned into various vectors, of which some of them containing an eukaryotic promoter, such as CMV promoter or RSV promoters. The transfection of two of these vectors, which

35

individually carries the segment A cDNA and segment B cDNA of the very virulent strain HK46, into CEF together, can not yield a viable virus.

A preferred IBDV mutant according to the invention can propagate in CEF or cell lines as a result of point mutation and/or a deletion and/or insertion of an  
5 oligo- or polynucleotide sequence in the gene encoding VP2.

Preferably, the mutation can be introduced in the IBDV segment A genomic region encoding the VP2 having an amino acid sequence (SEQ ID NO:32) shown in SEQ ID NO:1. The nucleic acid sequence of the whole segment A genome was determined and is shown in SEQ ID NO:1.

10 In addition, the mutation can be introduced in the IBDV segment B genomic region encoding the VP1 having an amino acid sequence (SEQ ID NO:33) shown in SEQ ID NO:2. The nucleic acid sequence of the whole segment B genome was determined and is shown in SEQ ID NO:2.

Certain amino acid residues encoded by the segment A cDNA inserts cloned  
15 into the vectors can be mutated by site-directed mutagenesis or PCR at one or more amino acid residues at positions 222, 249, 254, 256, 279, 284, 294, 299, 326 to 332 and combinations thereof. The transfection of certain mutated vectors together with the vector carrying the segment B cDNA insert into CEF can yield viable viruses, which are in the embodiment of this invention.

20 In a particular preferred embodiment of the invention, the viable mutant virus consists of substitutions at the amino acids residues 249(Q--> K) and 254(G-->S) of segment A protein, which can be passaged in CEF.

In another particular preferred embodiment of the invention, the viable mutant virus consists of substitutions at the amino acids residues 279(D-->N),  
25 254(A-->T) of segment A protein, which can be passaged in CEF.

According to the present invention such mutant IBDVs are generated in a controlled, non-random manner. The mutation introduced into the viruses are site-directed and the mutations can result in the change of the virulence and antigenicity of the virus.

30 Although, the IBDV mutant according to the invention is derived from strain HK46, an isolate recovered from infected tissues of 6 week old broilers by the Agricultural and Fishery Department of the Hong Kong Special Administration Region, any IBDV strain can be used to prepare the IBDV mutant, e.g. the very virulent strains G9201, G9303, F9502, the classical CJ801 and the variant strain

35



GZ902 described in a publication (Cao, Y. et al, Avian Dis. 42, 340-351, (1998)), or any newly evolved virulent strains.

From the cDNA derived from the genome segment A of any other IBDV, the NdeI-SpeI restriction fragment (nucleotides 652-1192) can be subcloned into the  
5 vectors containing SEQ ID NO:1. The vectors generated thereof can be used for mutagenesis as described above to generate cell culture-adapted, attenuated virus.

IBDV mutants according to the invention can also be obtained by inserting a nucleic acid sequence into the VP2 coding region. Such a nucleic acid sequence can inter alia be an oligonucleotide, for example of about 10-90 bp, or a gene encoding  
10 a polypeptide. Said nucleic acid sequence can be derived from any source, e.g. synthetic, viral, prokaryotic or eukaryotic.

The live recombinant vaccine generated according to this invention is administered in amounts sufficient to stimulate the immune system to confer resistance to IBD. The vaccine according to the invention is administered in such  
15 amount that will induce immunity in a chicken against challenge by a virulent IBDV. Immunity is defined as the induction of a significant level of protection in a population of chickens after vaccination compared to an unvaccinated group. A dose of  $10^2$  to  $10^5$  EID<sub>50</sub> of the IBDV mutant per chicken is recommended in general. The vaccine according to the invention may also be in a lyophilized form.

20 In addition to the IBDV recombinant vaccine described above, a vaccine according to the invention also comprises a pharmaceutically acceptable carrier compatible with the IBDV recombinant vaccine. As a pharmaceutically acceptable carrier a sterilized isotonic solution such as a physiological saline and a phosphate buffer may be added to the IBDV recombinant vaccine. Further suitable excipients  
25 are skimmed milk, glycerol, dextrose, sorbitol, starch, mannitol and the like. In addition, if desired, the vaccine can contain amounts of auxiliary substances which enhance the effectiveness of the vaccine, such as emulsifiers and adjuvants. Adjuvants such as aluminum hydroxide, aluminum phosphate, plant and mineral oil and the like, are administered with the vaccine in amounts adequate to enhance  
30 the immune response to the IBDV. The amount of adjuvant added to the vaccine will vary dependent on the nature of the adjuvant.

For administration to animals, the live IBDV recombinant vaccine can be given to the animal orally, nasally, ophthalmically, intradermally, subcutaneously, intramuscularly or by aerosol, spray and drinking water. It can also be given to  
35 fertilized eggs by in ovo injection. It is preferred to vaccinate the chickens by mass

administration techniques such as by placing the vaccine in drinking water or by spraying the vaccine.

An live IBDV recombinant vaccine according to the invention can also be used to prepare an inactivated vaccine, which can be administered by injection.

- 5 Parenteral administration of the inactivated vaccine can be carried out intradermally, subcutaneously, intramuscularly.

The recombinant vaccine generated by this invention is administered to poultry, including breeders, broilers, chickens, hens, layers, roasters, roosters and turkeys. Preferably, the vaccine is administrated to the poultry to prevent IBD before  
10 birth, and after hatching.

### EXAMPLES

#### Example 1

Propagation and Purification of IBDV from Bursae

- 15 The very virulent strains of infectious bursal disease virus (IBDV), HK46, G9303, G9201, and F9502, which were isolated in the southern part of P R China, were propagated in SPF chickens at 5 weeks of age. At 72 hr post-infection, the bursa were removed and homogenized in TNE buffer (10 mM Tris/HCl, 100 mM NaCl, 1 mM EDTA, pH8.0). After freezing and thawing for three times, the  
20 homogenates were centrifuged at 14 000 rpm for 15 min at 4°C, and the supernatants were collected for virus purification. One ml of bursal homogenate supernatants were loaded onto 4 ml of 40% sucrose cushion and ultracentrifuged at 55,000 g (Beckman sw55Ti rotor, 22,000 rpm) for 2.5 hr at 4°C. After removing the cushion, the virus particle pellets at the bottom were stored at -20°C.

25

#### Example 2

Extraction of Viral RNA

- Purified IBDV particles were resuspended in proteinase buffer (TNE + 0.5%SDS), digested with 1 mg/ml proteinase K for 1 hr at 37°C, and extracted with  
30 phenol-chloroform-isoamylalcohol (25:24:1, V/V) twice. Finally the viral dsRNA were precipitated from the upper aqueous-phase by ethanol.

#### Example 3

Synthesis of cDNA by Reverse Transcriptase

35

The cDNA of IBDV segments A and B of the very virulent strain, HK46, were synthesized independently. Two primer pairs, designated as A5 (SEQ ID NO: 3) with EcoR I site and A3 (SEQ ID NO: 4) with Kpn I site, B5 (SEQ ID NO: 5) with EcoR I site and B3 (SEQ ID NO: 6) with Xba I site, were used for synthesizing cDNA of IBDV segments A and B. Viral ds RNA mixed with primers A5 and A3 (for segment A) or B5 and B3 (for segment B) were denatured by boiling for 5 min and cooled on ice for 2 min. After adding equal volume of 2X PCR buffer containing 10 mmole of dNTPs, 50 mmole of MgCl<sub>2</sub>, 200 mmole of DTT and 200 U of SuperScript II RT (life Technologies), a total volume of 50 ul of reaction mixture was incubated at 50°C for 1 hr to synthesize the first strand cDNA. The reaction was terminated at 70°C for 15 min and the ds RNA was then digested by 1 U of RNase H at 37°C for 20 min.

#### Example 4

##### 15 PCR Amplification of the Whole IBDV Genome

All primers used for PCR and mutagenesis are listed in Table 1. Four fragments, designated as FA5 (5' end fragment of segment A), FA3 (3' end fragment of segment A), FB5 (5' end fragment of segment B), FB3 (3' end fragment of segment B), were independently amplified by Expand<sup>TM</sup> High Fidelity PCR System (Boehringer Mannheim), using the first strand cDNA as templates. The amplifications were performed using Robocycler<sup>®</sup> Gradient 96 (Stratagene) following the program of 94°C for 3 min; 30 cycles of 94°C for 40 sec, 60°C (for FA5 and FA3 amplification) or 52°C (for FB5 and FB3 amplification) for 40 sec, 72°C for 2 min 30 sec; and finally 72°C for 10 min. Four primer pairs were used for amplifications of the corresponding fragments, in which A5 (SEQ ID NO:3) and A3AP (SEQ ID NO:7) were used for amplifications of fragment FA5, A5SP (SEQ ID NO:8) and A3 (SEQ ID NO:4) for fragment FA3, B5 (SEQ ID NO:5) and B3AP (SEQ ID NO:9) for fragment FB5, B5SP (SEQ ID NO:10) and B3 (SEQ ID NO:6) for fragment FB3.

30

35

TABLE 1. Primers for genome cloning and mutagenesis of IBDV

	SEQ IDNO:	Na me	Size (bp)	RE site	direc tion	locatio n	sequence
5	3	A5	40	Eco RI	+	A,5' end	5'ATGAATTCAGGATACGATCGGTCTGAC CCCGGGGGAGTCA3'
	4	A3	33	Kpn I	-	A,3' end	5'TAGGTACCAAGGGACCCGCGAACGGAT CCAATT3'
	5	B5	29	Eco RI	+	B,5' end	5'TTAGAATTCTAGGATACGATGGGTCTGA C3'
10	6	B3	29	Xba I	-	B,3' end	5'ATTTCTAGATGGGGGCCCGCAGGCG AA3'
	7	A3A P	27	Sal I	-	A, 1729- 1755	5'CAGGTGAAGCARAGAATCCCGTCGACT A3'
	8	A5S P	28	Sal I	+	A, 1718- 1745	5'CCAGAATCCYGTAGTCGACGGGATTCTT 3'
15	9	B3A P	21	Bgl II	-	B, 1848- 1868	5'GATCCCRAGATCTTTGCTGTA3'
	10	B5S P	24	---	+	B, 1757- 1780	5'CCTTGCACAACCAGGGTACCTGAG3'
20	11	NT A	34	---	-	A, 956- 989	5'GGTCGTTAGCCCATTGTTTCGGGCCACA GCTCTG3'
	12	NTS	38	---	+	A, 969- 1006	5'GCAAACAATGGGCGAACGACCGGCACT GACAACCTTAT3'
	13	KSA	35	---	-	A, 866- 900	5'GGCTTTGGAEGCTTGTTTTAAACACGAG CTCTCCC3'
25	14	KSS	33	---	+	A, 881- 913	5'TAAAACAAGCGTCCAAAGCCTTATACTT GGGTGC3'
	15	33O R	27	---	-	A, 1115- 1141	5'pACTGCTAGGCTCCCTCTTGCTGACCAT 3'
	16	mu t-KS	35	---	-	A, 873- 907	5'pAGTATAAGGCTTTGGACGCTTGTTTTA AACACGAG3'
30	17	mu t- NT	36	---	-	A, 963- 998	5'pGTCAGTGCCGGTCGTTAGCCCATTGTT TGCGGCCAC3'

R = A or G; Y = C or T

### Example 5

#### Construction of Full Length cDNA Clones of IBDV Genome

Full-length cDNA clones of IBDV segments A and B genome were independently prepared. To obtain cDNA clones of segment A of HK46 strain, two cDNA fragments FA5 and FA3 were amplified by PCR using two primer pairs, A5 (SEQ ID NO:3) and A3AP(SEQ ID NO:7), A5SP(SEQ ID NO:8) and A3(SEQ ID NO:4) and using first strand cDNA of segment A as template. Fragment FA5 digested with EcoR I and Sal I was cloned into the EcoR I/Sal I site of pBssK vector (Stratagene) to obtain plasmid FA5-pBssK. After digesting fragment FA3 and plasmid FA5-pBssK with Sal I and Kpn I, the insert (FA3) and the vector (FA5-pBssK) were ligated with T4 DNA-ligase. After transforming the ligated DNA into E.coli XL1-Blue strain, positive colonies were screened by PCR. Plasmid DNAs are extracted from positive colonies by a mini-prep kit (Wizard Plus Minipreps DNA purification system, Promega) and their identities were confirmed by digestion with EcoR I and Kpn I. The size of the plasmid FA-pBssK is about 6.2kb. This plasmid contains a full-length cDNA copy of segment A of IBDV HK46 (Fig.3).

To obtain cDNA clones of segment B of HK46, two fragments FB5 and FB3 were amplified by PCR using two primer pairs, B5 (SEQ ID NO:5) and B3AP(SEQ ID NO:9), B5SP(SEQ ID NO:10) and B3(SEQ ID NO:6), respectively, and using first strand cDNA of segment B as template. There is an unique Bgl II site in the overlapping region of fragments FB5 and FB3. Because pBssK vector lacks Bgl II site, another plasmid pBssK-Bgl, in which an unrelated cDNA containing Bgl II sites was cloned into the EcoR I site of pBssK, was employed to construct full-length cDNA clones of fragment B. Fragment FB3 digested with Bgl II and Xba I was cloned into the Bgl II/Xba I site of plasmid pBssK-Bgl to obtain plasmid FB3-pBssK. After digesting fragment FB5 and FB3-pBssK with EcoR I and Bgl II, the insert (FB5) and the vector (FB3-pBssK) were ligated with T4 DNA ligase. After transforming the ligated DNA into E.coli XL1-Blue strain, positive colonies were screened by PCR. Plasmid DNAs were extracted from positive colonies by a mini-prep kit (Wizard Plus Minipreps DNA purification system, Promega) and their identities were confirmed by digestion with EcoRI and XbaI. The size of the plasmid FA-pBssK is about 5.7 kb. Therefore this plasmid contains a full-length cDNA copy of segment B of IBDV HK46 strain, but does not contain the unrelated cDNA fragment (Fig.4).

### Example 6

#### 35 DNA Sequencing

PCR sequencing reactions were carried out using an Autocycle DNA Sequencing Kit (Pharmacia) following the manufacturer's recommended conditions. Specific primers with fluorescein at 5' end, as listed in table 2, were used for the sequencing. Sequence determination was performed using Automated Laser  
5 Fluorescein (ALF) nucleotide sequencer (Pharmacia). Sequences data were assembled and analyzed using the GCG package (Genetics Computer Group, Madison, Wisconsin, USA). Phylogenetic trees were prepared by the UPGMA method (Unweighted Pair Group with Arithmetic Mean) of the GeneWorks program (IntelliGenetics Inc, Mountain View, CA, USA).

10

15

20

25

30

35

TABLE 2. Primers for DNA sequencing

SEQ IDNO:	Name	Size (bp)	direct ion	locati on	Sequence
5	18	A639S	19	+	639- 5'AGCTTACCCACATCATATG3' 657
	19	A723A	17	-	723- 5'TCACTGCTGTCACATGT3' 739
10	20	A768S	20	+	768- 5'GCCGATGATTACCAATTCTC3' 787
	21	A1041 S	17	+	1041- 5'ACCCAGCCAATCACATC3' 1057
	22	A1405 S	16	+	1405- 5'CGGAGTACTTCATGGA3' 1420
15	23	A1835 S	16	+	1835- 5'GGAAGACGCCATGACA3' 1850
	24	A2174 S	18	+	2174- 5'CTATGGCGAGATTGAGAA3' 2191
20	25	A2538 S	17	+	2538- 5'ATGGCCAACTTCGCACT3' 2554
	26	B296S	17	+	296- 5'CAAGATTCTGCAGCCAC3' 312
25	27	B429S	17	+	429- 5'CAGGAGTACTTCCCAAA3' 446
	28	B876S	19	+	876- 5'AACCTCAAGTCATCAAGTG3' 894
30	29	B1029 A	17	-	1029- 5'TCACTTAGCATGCTGAG3' 1045
	30	B1229 S	19	+	1229- 5'GTCACTCTACAAGTTCAAC3' 1247
35	31	B2568 A	17	-	2568- 5'GTCTGTGGGTTCTTAAC3' 2584

### Example 7

#### Site-directed Mutagenesis by PCR

According to the results of sequence analysis of VP2 cDNA of IBDV, amino  
5 acid substitutions at position 279 (D@N) and 284 (A@T), as well as in the serine-  
rich heptapeptide region (330 S@R), may result in the reduced virulence of classical  
IBDV strains. In addition, two other specific amino acid residues, 249K and 254S,  
may be the signature residues of the variant IBDV strains. So three combinations of  
mutations were introduced to the segment A cDNA of strain HK46: (a) Mutant NT:  
10 substitutions at nucleotide positions 966 (G@A) and 981 (G@A) can result in amino  
acid substitutions at residues 279(D@N) and 284(A@T); (b) Mutant KS: nucleotide  
substitutions at positions 876 (C@A) and 891 (G@A) can result in amino acid  
substitutions at residues 249(Q@K) and 254 (G@S); (c) Mutant R: nucleotide  
substitution at position 1121 (T@A) can result in amino acid substitution at position  
15 330 (S@R).

To introduce the mutation sequences into segment A of IBDV, plasmids NT-  
FA-pBssK and KS-FA-pBssK were constructed by oligo-nucleotide directed  
mutagenesis, or by using specific primer pairs and FA-pBssK as template in PCR  
reactions. To construct plasmid NT-FA-pBssK, two primer pairs, designated as A5  
20 (SEQ ID NO: 3) and NTA (SEQ ID NO: 11), NTS (SEQ ID NO: 12) and A3AP (SEQ  
ID NO: 7), were used to amplify two DNA fragments of 991 and 786 bp,  
respectively. These two DNA fragments were purified, combined and reamplified by  
PCR using the primers A5 and A3AP. Pfu polymerase (Stratagene) was used in the  
PCR reaction to increase the fidelity. To increase the yield of the combined  
25 fragment, five cycles of 94°C for 2 min, 50°C for 1 min and 72°C for 2 min were run  
without adding any primers in the PCR cocktails. Subsequently, the primer pair A5  
and A3AP was added into the PCR mixtures, and the amplification was performed  
following the program of 94°C for 3 min, 30 cycles of 94°C for 40 sec, 60°C for 40  
sec, 72°C for 2 min 30 sec, and finally 72°C for 10 min. After amplification, the PCR  
30 product of 1756 bp were then digested with EcoR I and Sal I. The resulting  
fragment of 1726 bp was cloned into the EcoR I / Sal I site of FA-pBssK to substitute  
the EcoR I/Sal I insert of the plasmid FA-pBssK to obtain the plasmid NT-FA-pBssK.  
The mutated sequences were confirmed by cycling PCR sequencing. The plasmid  
NT-FA-pBssK contains full-length cDNA of segment A of HK46 strain but has  
35 substitutions at nucleotide positions 966 (G@A) and 981 (G@A).



To construct plasmid KS-FA-pBssK, two primer pairs, A5 (SEQ ID NO: 3) and KSA (SEQ ID NO: 13), KSS (SEQ ID NO: 14) and A3AP(SEQ ID NO: 7), were used to amplify the DNA fragments of 902 and 874 bp respectively, using FA-pBssK as template. A PCR product of 1756 bp was then amplified from the two PCR products as described above, which was subsequently cloned into the EcoRI/SalI site of the plasmid FA-pBssK. The mutated sequences were confirmed by cycling PCR sequencing using sequencing primers. The new plasmid KS-FA-pBssK contains full-length cDNA of segment A of HK46 but has substitutions at nucleotide positions 876 (C®A) and 891 (C®A).

10

#### Example 8

#### Mutation of the Serine-rich Heptapeptide Region on VP2 Using Altered Sites II Mammalian Mutagenesis System

Carrying the genes for ampicillin / chloramphenicol resistance and CMV I.E. enhancer / promotor, the pALTER-MAX vector may be used for mutagenesis and expression of genes in eukaryotic cells (Promega). In this study, the segment A cDNA (SEQ ID NO:1) of strain HK46 was subcloned into the pALTER-MAX vector. The plasmid FA-pBssK was digested with EcoR I, Kpn I and Bgl I. Because there is an unique Bgl I site in the pBssK vector but not in the sequence of fragment FA, the fragment FA and pBssK can easily be separated by 1% agarose gel after the plasmids were digested with Bgl I. After digestion, the FA fragment (3269 bp) was purified and cloned into the EcoR I/Kpn I site of pALTER-MAX vector to create plasmid FA-pALTER.

To substitute serine at amino acid residue 330 with arginine, the nucleotide T at position 1127 was changed to A using Altered sites II mammalian mutagenesis system (Promega). The single strand (ss) DNA of plasmids FA-pALTER and was produced using the methods recommended by supplier. A primer designated as 330R (5'ACTGCTAGGCTCCCTCTTGCGGA CCA3') that was phosphorylated at the 5'-end was synthesized and used for producing a mutation on plasmid FA-pALTER in which the nucleotide 1127(T) was substituted with A. Twenty microliters of annealing reaction mixture containing 0.05 pmole of ssDNA of FA-pALTER, 1.25 pmole of primer 330R, 0.25 pmole of ampicillin repair oligonucleotide, 20mM Tris-HCl (pH7.5), 10 mM MgCl<sub>2</sub> and 50 mM NaCl was heated to 75°C for 5 min, and then cooled slowly down to room temperature. After adding 3 ul of synthesis buffer containing 100 mM Tris-HCl (pH7.5), 5 mM dNTPs, 10 mM ATP and 20 mM DTT,

ten units of T<sub>4</sub> DNA polymerase and 3 units of T4 DNA ligase were mixed with annealing reaction mixture, and the total volume of DNA synthesis reaction was adjusted to 30 ul with deionized water. Subsequently, synthesis mixture was incubated at 37°C for 2 hr to perform mutant strand synthesis and ligation. After  
5 incubation, the synthesis mixture was transformed into E coli strain ES1301 mutS competent cells by electroporation. The transformed ES1301 mutS cells were resuspended in 1 ml of LB broth without any antibiotics, and incubated at 37°C for 3 hr. By adding 0.5 ml of transformed cell culture to 4.5 ml of selective medium (LB broth with 100 ug/ml ampicillin), the transformed ES1301 mutS cells were cultured  
10 at 37°C with shaking at 250rpm overnight. Plasmid DNA was then extracted by the Wizard<sup>a</sup> Plus Minipreps DNA purification system and then transformed into Ecoli strain JM109 competent cells. Ten colonies were screened by direct sequencing with primer A768S (SEQ ID NO: 20) using an automatic sequencer. The resulting mutant plasmid designated as R-FA-pALTER was obtained.

15

#### Example 9

##### Generation of Recombinant viruses by Transfection

The segment A cDNAs from plasmids FA-FA-pBssK, NT-FA- pBssK, KS-FA- pBssK and R-FA-pALTER were released by EcoR I, Kpn I and Bgl I digestion and  
20 then subcloned into a plasmid at a site downstream to a CMV promoter. To clone the fragment FB into this plasmid, the plasmid FB-pBssK was digested with three restriction enzymes EcoR I, Xba I and Pvu II, where Pvu II can only digest pBssK vector but can not digest fragment FB. Subsequently the fragment FB was purified and inserted into the EcoR I/ Xba I site of the plasmid carrying a CMV promoter. This  
25 plasmid contained the full-length cDNA copy of segment B downstream to a CMV promoter.

The CEFs were grown to 80% confluence in a 12-well tissue culture plate (Falcon) and washed once with phosphate-buffered-saline (PBS). One ml of serum free EME medium (SF-EMEM) (Life Technologies) were added to monolayers of  
30 each well, and the cells were incubated at 37°C for 1 hr in 5% CO<sub>2</sub> incubator. 5ul (0.2ug/ul) of both plasmids, CMV-FA and CMV-FB were then transfected to the CEF by Lipofectamine (Life Technologies), according to the manufacturer's procedures. After 5 hr of incubation at 37°C, the transfection mixture was replaced with EMEM containing 10% FBS, and the cells were further incubated at 37°C in 5% CO<sub>2</sub>  
35 incubator for desired time intervals. The plasmids containing mutants of segment A

cDNAs (KS-FA or NT-FA or R-FA) and/or CMV-FB were also transfected into CEF using the same procedure described above. After 96 hours, cytopathic effect was observed. The ability of the recombinant viruses in propagating in CEF was further tested by adding 0.1 ml virus suspension collected 96 hr posttransfection into a well of a 12 well plate containing 80% confluent CEF with 1 ml cell culture medium. The results on transfection and virus propagation are summarized in Table 3.

TABLE 3. CPE on CEF monolayers transfected by plasmids containing full-length cDNA of both segments A and B of HK46 strain or its mutants. The presence of virus was tested by passages in CEF cells.

	R1	R2	NT	KS	FA
Transfection I: (96 hrs after transfection)	+	+	+	+	-
Transfection II (96hrs after transfection)	+	+	+	+	-
Passage one in CEF (with transfection I)	-	-	+	+	-
Passage two in CEF	-	-	+	+	-

R1, R2: Transfected with two independent CMV-R plasmids and CMV-FB plasmid.

NT: Transfected with CMV-NT-FA plasmid and CMV-FB plasmid.

KS: Transfected with CMV-KS-FA plasmid and CMV-FB plasmid.

FA: Transfected with wild-type CMV-FA plasmid and CMV-FB plasmid.

#### Example 10

Confirmation of antigenic sequence of the recombinant virus by DNA sequencing

After virus propagation in CEF, cell debris was removed from the supernatant by centrifugation at 14,000rpm for 20min at 4°C. One ml of supernatant was loaded onto 4 ml of 40%(v/v) sucrose cushion and ultracentrifuged at 55,000g (Beckman sw55Ti rotor, 22,000rpm) for 2.5 hr at 4°C. The virus at the pellet was processed as stated in Examples 3&4 to produce first stranded cDNA. PCR reaction as stated in Example 5 was carried out to amplify the 5'cDNA segment of genome A (equivalent to FA5), which was then sequenced to confirm the mutation (Table 2).

Example 11

## Animal tests

The recombinant virus (HK46-NT) generated from transfection was passaged and titred in CEF. To compare its pathogenicity with its parent strains,  
5 3.2x10<sup>5</sup>TCID<sub>50</sub> HK46-NT and 1.6x10<sup>5</sup>EID<sub>50</sub> HK46 were administrated to 4 weeks old SPF birds. No birds vaccinated with HK46-NT showed any symptoms nor mortality, whereas all birds challenged by the parent strain HK46 were sick and the mortality reached 60%. The weights of the bursa after challenge were recorded in figure 5. To test the immunogenicity of HK46-NT, it was administrated to SPF  
10 chickens at 25 days old (10<sup>6</sup>TCID<sub>50</sub>/bird) and antibody titre at 43 days old was measured by a commercial ELISA kit (Idexx Inc.). The signal-to-noise (S/N) ratios were 3.41 +/- 0.68 and 1.37 +/- 0.13, respectively.

While the present invention has been described in a number of different exemplary embodiments, it will be understood that the principles of the invention  
15 can be extended to still further embodiments and that the embodiments illustrated here are not intended to limit the scope of the invention as set forth in the appended claims.

20

25

30

35

WHAT IS CLAIMED IS:

1. A biological pure RNA encoding SEQ ID NO:1 or a fragment thereof of  
from 1 to 1012 amino acids long; or a biological DNA encoding to said biological  
5 pure RNA. (v.v. IBD segment A)
2. A biological pure RNA encoding SEQ ID NO:2 or a fragment thereof of  
from 1 to 879 amino acids long; or a biological DNA encoding to said biological  
pure RNA. (v.v. IBD segment B)  
10
3. The biological pure DNA of claim 1, consisting of SEQ ID NO:1.
4. The biological pure DNA of claim 2, consisting of SEQ ID NO:2.
- 15 5. The biological pure DNA of claim 3, consisting of one or more  
nucleotide substitutions generated by mutagenesis using molecular approaches.
6. The biological pure DNA of claim 4, consisting of one or more  
nucleotide substitutions generated by mutagenesis using molecular approaches.  
20
7. The biological pure DNA of claim 3, consisting of one or more  
nucleotide substitutions resulting in point mutations at one or more amino acid  
residues at positions 222, 249, 254, 256, 279, 284, 294, 299 and 326 to 332.
- 25 8. A recombinant vector consisting of the biological pure DNA of claim 5.
9. A recombinant vector consisting of the biological pure DNA of claim 6.
10. A recombinant vector consisting of the biological pure DNA of claim 7.  
30
11. The generation of recombinant infectious bursal disease virus by the  
co-transfection of the recombinant vectors of claims 8 and 9.
12. The generation of recombinant infectious bursal disease virus by the  
35 co-transfection of the recombinant vectors of claims 9 and 10.

13. An recombinant infectious bursal disease virus generated by the procedures described in claim 11, comprising mutations at one or more of the amino acid residues, wherein the IBDV mutant acquire the ability of propagation in chicken embryo fibroblasts, or other primary tissue culture or cell lines.

5

14. An recombinant infectious bursal disease virus generated by the procedures described in claim 12, comprising mutations at one or more of the amino acid residues, wherein the IBDV mutant acquire the ability of propagation in chicken embryo fibroblasts, or other primary tissue culture or cell lines.

10

15. An recombinant infectious bursal disease virus generated by the procedures described in claim 11, comprising mutations at one or more of the amino acid residues at positions 249, 254, 279, 284, 326 to 332 of the SEQ ID NO:1, wherein the IBDV mutant acquires the ability of propagation in chicken embryo fibroblasts, or other primary tissue culture or cell lines.

15

16. An recombinant infectious bursal disease virus generated by the procedures described in claim 12, comprising mutations at one or more of the amino acid residues at positions 249, 254, 279, 284, 326 to 332 of the SEQ ID NO:1, wherein the IBDV mutant acquires the ability of propagation in chicken embryo fibroblasts, or other primary tissue culture or cell lines.

20

17. An IBDV mutant according to claim 13, wherein the mutation is selected from the group consisting of a deletion, an insertion, and a deletion and insertion and point mutations.

25

18. An IBDV mutant according to claim 15, wherein the mutation is selected from the group consisting of a deletion, an insertion, and a deletion and insertion and point mutations.

30

19. An IBDV mutant according to claim 13, wherein at least one heterologous nucleic acid fragment from a virus or a pathogen encoding a polypeptide is inserted into the VP2 locus.

35

20. An IBDV mutant according to claim 15, wherein at least one heterologous nucleic acid fragment from a virus or a pathogen encoding a polypeptide is inserted into the VP2 locus.

5 21. A cell infected with an recombinant IBDV mutant according to claim 13.

22. A cell infected with an recombinant IBDV mutant according to claim 15.

10 23. A cell infected with an recombinant IBDV mutant according to claim 17.

24. A cell infected with an recombinant IBDV mutant according to claim 15 19.

20

25

30

35

143

Accession	Protein	Sequence	Consensus
HK46	.....	.....	.....
UK661	.....	.....	.....
G9201	.....	.....	.....
F9502	.....	.....	.....
G9303	.....	.....	.....
52/70	.....	.....	.....
STC	.....	.....	.....
CJ801	.....	.....	.....
Variant-A	.....	.....	.....
Variant-E	.....	.....	.....
GZ902	.....	.....	.....
GLS	.....	.....	.....
CJ801BKF	.....	.....	.....
CU-1	.....	.....	.....
PBG-98	.....	.....	.....
GZ911	.....	.....	.....
002-73	.....	.....	.....
Consensus	GLMSATANIN	DKIGNVLVGE	GVTVLSLPTS YDLGYVRLGD PIPAICLDPK MWATCSDSR PRVYTTIAA D DYQFSSQYQP

**FIG. 1A**



223

HK46	I . . . I . . . I . . . I . . . I . . . S.
UK661	I . . . I . . . I . . . I . . . f . . . S.
G9201	I . . . I . . . I . . . I . . . I . . . S.
F9502	I . . . I . . . I . . . I . . . I . . . S.
G9303	I . . . I . . . I . . . I . . . I . . . S.
52/70	I . . . I . . . I . . . I . . . I . . . S.
SIC	. . . . . I . . . I . . . I . . . S.
CJ801	I . . . D . . . I . . . N . . . I . . .
Variant-A	K . . . S . . . N . . . I . . .
Variant-E	K . . . S . . . N . . . I . . .
GZ902	K . HS . . . N . . . T . I . .
GLS	K . HS . . . S . . . T . . .
CJ801BKF	H . H . . . I . . . T . . .
Cv-1	H . H . . . I . . . NT . . . S.
PBG-98	R . H . . . I . . . NT . . .
GZ911	H . H . . . V . . . T . . . L . . .
002-73	N . . . . . N . . . V . . . T . . . G . . . S.
CONSENSUS	G VTITLFSANIDAITSLSV GGELVFQTSV QGVLGCATTY LGCFDGTAVI TRAAADNGL TAGTGNLMPF NLVIPTNEITT

**FIG. 1B**

303

[illegible]

**FIG. 1C**

4/7




FIG. 2

5/7




FIG.3

6/7




FIG.4

7/7




FIG.5

## SEQUENCE LISTING

&lt;110&gt; VERSITECH LTD.

<120> GENERATION OF RECOMBINANT INFECTIOUS BURSAL DISEASE  
VIRUSES BY REVERSE GENETICS TECHNOLOGY AND THE USE OF  
THE RECOMBINANT VIRUSES AS ATTENUATED VACCINES

&lt;130&gt; 9661-003-228

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; 60/098,684

&lt;151&gt; 1998-09-01

&lt;160&gt; 33

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 3269

&lt;212&gt; DNA

&lt;213&gt; Infectious bursal disease virus

&lt;400&gt; 1

```

aggatcagat cggtctgacc ccgggggagat caccggggga caggctgaca aggccttgtt 60
ccaggatgga actcctcctt ctacaatgct atcattgatg gttagtagag atcagacaaa 120
cgatcgcagc gatgacgaac ctgcaagatc aaacccaaca gattgttccg ttcatacggg 180
gccttctgat gccacaacc ggaccggcgt ccattccgga cgacacccta gagaagcaca 240
ctctcaggtc agagacctcg acctacaatt tgactgtggg ggacacaggg tcaggggctaa 300
ttgtcttttt ccctgggttt cctgggtcaa ttgtgggtgc tcactacaca ctgcagagca 360
atgggaacta caagtctgat cagatgtctc tgactgcccga gaacctaccg gccagctaca 420
actactgcag gctagttagt cggagtctca cagttaggtc aagcacactc cctgggtggc 480
tttatgcact aaatggcacc ataaacgcgc tgaccttcca aggaagcctg agtgaactga 540
cagatgttag ctacaatggg ttgatgtctg caacagccaa catcaacgac aaaatcggga 600
acgtcctagt aggggaaggg gtaaccgtcc tcagcttacc cacatcatat gatcttgggt 660
atgtgagact cgtgacccc attcccgtca tagggctcga cccaaaaatg gtagcaacat 720
gtgacagcag tgacaggccc agagtctaca ccataactgc agccgatgat taccaattct 780
catcacagta ccaagcaggg ggggtaacaa tcacactgtt ctcagctaat atcgatgcca 840
tcacaagcct cagcatcggg ggagaactcg tgtttcaaac aagcgtccaa ggccttatac 900
tgggtgctac catctacctt ataggctttg atgggactgc ggtaatcacc agagctgttg 960
ccgcagacaa tgggctaacg gccggcactg acaaccttat gccattcaac attgtgattc 1020
caaccagcga gataacccag ccaatcacat ccatcaaaact ggagatagtg acctccaaaa 1080
gtggtggtca ggcgggggat cagatgtcat ggtcagcaag tgggagccta gcagtacga 1140
tccacggagg caactaccca ggggccctcc gtcccgtcac actagtagcc tacgaaagag 1200
tggcaacagg gtctgtcggt acggtcgcgc ggggtgagcaa ctctgagctg atcccaaatc 1260
ctgaactagc aaagaacctg gtcacagaat acggccgatt tgacccaggg gccatgaact 1320
acacaaaatt gatactgagt gagagggacc gtcttggcat caagaccgta tggccaacaa 1380
gggagtacac tgactttcgc gactacttca tggaggtggc agacctcaac tctcccctga 1440
agattgcagg agcatttggc ttcaaggaca taattcgggc actaaggagg atagctgtgc 1500
cgggtggtct tacactgttc ccacccgcgc ctcccctagc ccatgcaatt ggggaagggt 1560
tagactacct gctggcgat gagacacagg ctgcttcagg aactgctcga gccgcgtcgg 1620
gaaaagcaag agctgcctca ggccgcataa ggcagctaac tctcgcgcgc gacaaggggt 1680
acgaggtagt cgcgaatctg ttccaggtgc ccgagaatcc tgtagtcgac gggattcttg 1740
cttcacctgg gatactccgc ggtgcacaca acctcgactg cgtgttgaga gaggggtgcca 1800
cgctattccc tgtggtcatc acgacagtgg aagatgccat gacacccaaa gcaactgaaca 1860

```

```

gcaaaaatggtt tgctgtcatt gaaggcgtgc gagaagatct ccaacctcca tctcaaagag 1920
gaccccttcat acgaactctc tccggacata gagtctatgg atatgtcca gatggggtac 1980
ttccactgga gactgggaga gattacaccg tggccccaat agatgatgtc tgggacgaca 2040
gcattatgct gtccaaagac cccataccctc ctattgtggg aaacagcgga accctagcca 2100
tagcttacat ggatgtgttt cgacccaaag tccccatcca tgtggccatg acgggagccc 2160
tcaacgccta tggcgagatt gagaacgtga gctttagaag caccaagctc gccactgcac 2220
accgacttgg ccttaagttg gctgggtccc gtgcatttga cgtgaacacc ggggtccaact 2280
gggcgacgtt tatcaaacgt tttccccaca atccacgcga ctgggacagg ctcccttacc 2340
tcaaccttcc ataccttcca cccaatgcag gacgccagta cgacctggcc atggccgctt 2400
cagagttaa agagaccccc gaactcgaga gcgccgtcag agccatggaa gcagcagcca 2460
acgtggaccc actgttccaa tctgcgtca gcgtgttcat gtggctggaa gagaatggga 2520
ttgtgactga tatggccaac ttcgcactta gcgaccgaa cgcccatcgg atgcgcaatt 2580
ttctcgcaaa cgcaccacaa gcaggcagca agtcgcaaa agccaagtac gggacagcag 2640
gctacggagt ggagggcccg ggccccactc cagaggaagc acagagggaa aaagacacac 2700
ggatctcaa gaagatggag actatgggca tctactttgc aacaccagaa tgggtagcac 2760
tcaacgggca ccgggggccc agccccggcc agctaaagta ctggcagaa acacgagaaa 2820
tacctgatcc aaacgaggac tacctagact acgtgcatgc agagaagagc cggttggcat 2880
cagaagaaca aatcctaagg gcggctacgt cgatctacgg ggctccagga caggcagagc 2940
caccacaggc ctttatagac gaggtcgcca aagtctatga aatcaaccat ggggtggcc 3000
ccaaccaaga acagatgaaa gatctgctct tgactgcgat ggagatgaag catcgcaatc 3060
ccaggcgggc tccaccaaag cccaagccaa aaccaatgt tccaacacag agacctcctg 3120
gtcggctggg ccgctggatc agggctgtct ctgatgagga ccttgagtga ggctcctggg 3180
agtctcccga caccaccgc gcaggcgtgg acaccaattc ggccgtacaa catcccaaat 3240
tggatccgtt cgcgggtccc cttggtacc 3269

```

<210> 2

<211> 2834

<212> DNA

<213> Infectious bursal disease virus

<400> 2

```

taggatacga tgggtctgac cctctgggag tcacgaatta acgtggctac taggggtgat 60
gccacacgct agctgccacg ttagtggtc ctcttcttga tgattctacc accatgagtg 120
acgttttcaa tagtcacacg gcgcgaagca agatatcagc agcgttcggc ataaagccta 180
cagttggaca ggatgtggaa gaactcctga tccctaaggt ctgggtgcca cctgaggatc 240
ccttggccag ccctagtcgt ctggccaagt tctcaggga aaacggttac aagattctgc 300
agccacggct tctacctgag aatgaggaat atgagaccga tcaaatactc cctgacctag 360
cttgagtag gcagatagag ggagctgtct taaaaccaac cctatctctc ccattggag 420
accaggagta cttccctaaa tactacccaa cacaccgcc gagcaaggaa aagcccaatg 480
cgtaccgcc cgatatcgcg ttactcaagc agatgatcta cttgtttctc caggttccc 540
aggccacaga taacctcaaa gatgaggtca cttactaac ccaaacatt agagataagg 600
cctacgggag tgggacctac atgggacagg ctaccagact tgttgctatg aaagagggtg 660
ccactgggag aaacccaaac aaagatcctc taaagcttgg gtacaccttt gagagcatag 720
cccagctact tgacatcact ttaccggtag gccaccgg tgaggatgac aagccctggg 780
taccactcac aagggtgccc tcaaggatgt tggttctgac gggcgacgta gatggggaat 840
ttgaggttga ggactacctt cccaaaatca acctcaagtc atcaagtggg ctgccctatg 900
ttggtcgcac caaaggagaa actattgggg agatgatagc catatcgaa cagtttctcc 960
gagagctatc agcgtgctg aagcaggggtg cagggacaaa agggtcgaac aagaagaagc 1020
tgctcagcat gctaagtgac tactggtact tatcatgtgg gcttttgttt cccaaggctg 1080
agaggtaacga caaaagcacg tggctacca agaccgtaa catatgggtc gctccatcac 1140
caacacacct catgatctca atgataacct ggcccgtgat gtccaatagc ccaaacaacg 1200
tgctgaacat tgaggggtgt ccgtcactct acaagttcaa ccggtttagg ggtgggctaa 1260
acagatcgt ggagtgata atggctccgg atgaacccaa ggccttagta tacgccgaca 1320
acatacatat tgttactctc aacacgtggg actcaattga cctagagaag ggcgaggcaa 1380
actgcacgcg tcaacacatg caggccgcca tgtactacat ccttaccaga ggatgggtcc 1440
ataacggtga ccccatgttc aatcagacat gggccacatt tgcgatgaac attgcccctg 1500
ctctagttgt ggactcatca tgcctgatta tgaaccttca gatcaagaca tatggtcaag 1560
gcagtgaggaa tgcagccacc ttcatacaaa accatcttct tggcaccctt gtgctagacc 1620

```



```

agtggaactt gatgaagcaa cccagtccag acagcgaaga gttcaagtca attgaagaca 1680
agctgggcat caacttcaag attgagaggt ccattgatga catcaggggc aagctcagac 1740
agcttggtccc ccttgacaaa ccagggtacc tgagtggagg ggtcgaacca gagcaaccca 1800
gccccactgt agagctggac ctactcggat ggtctgcaac ctacagcaaa gatcttggga 1860
tctatgtgcc ggtgcttgac aaggaacgct tattttgctc tgctgcgtat cccaaagggg 1920
tagagaacaa aagcctcaaa tccaagggtg ggatcgagca agcatacaaa gttgtcaggt 1980
acgaggcggt gaggttggtg ggtggttgga actaccact cctgaacaaa gcttgcaaga 2040
acaatgcaag tgcagctcgg cggcatctgg aggccaaagg gttcccgctc gatgagttcc 2100
tcgcccagtg gtcagagttg tccgagttcg gagaagcttt cgaaggcttc aacatcaagc 2160
tgacagtaac accggagagc ctccggaac ttaacagacc agtaccctcc aaacctccaa 2220
atgtcaacag accagtcaac accggtgggc taaaggcggc cagcaatgcc ctcaagaccg 2280
gccggtatag aatgaagcc ggactaagtg gcctcgtcct cctagccacc gccgcagcc 2340
gactacagga cgcagtcaag gccaaaggcag aggccgagaa actccacaag tctaagcccg 2400
atgaccccgga tgcagactgg tttgaacgat cagaaacctt gtcagacctg ctggagaaag 2460
ccgacattgc cagcaaggct gctcactcag cactcgtgga aacaagcgac gctcttgaag 2520
cgggtccagtc aacctcagtg tacaccccaa agtatccaga ggtaagaac ccacagaccg 2580
cctccaaccc cgttggtggg ctccacctgc ccgctaagag ggccaccggg gtccaggcag 2640
ctcttctcgg agcagggacg agcagaccaa tggggatgga gggtccaaca cgggtccaaga 2700
acgccgtgaa aatggccaaa aggcgggaac gccaaaaaga gagccgcca tagccatgat 2760
gggaaccact caagaagagg acactaaccc cagaccccggt atccccggcc ttcgcctgcg 2820
ggccccatc taga 2834

```

&lt;210&gt; 3

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Primer

&lt;400&gt; 3

atgaattcag gatacgatcg gtctgacccc gggggagtc

40

&lt;210&gt; 4

&lt;211&gt; 33

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Primer

&lt;400&gt; 4

taggtaccaa gggacccgcg aacggatcca att

33

&lt;210&gt; 5

&lt;211&gt; 29

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Primer

&lt;400&gt; 5

ttagaattct aggatacgat ggtctgac

29

&lt;210&gt; 6

&lt;211&gt; 29

&lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 6

atttctagat gggggccccc gcaggcgaa

29

<210> 7

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 7

cägggtgaagc ragaatcccg tcgacta

27

<210> 8

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 8

ccagaatccy gtagtcgacg ggattctt

28

<210> 9

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 9

gatcccraga tctttgctgt a

21

<210> 10

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 10

ccttgacaaa ccagggtacc tgag

24

<210> 11

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 11

ggtcgtagc ccattgtttc gggccacagc tctg

34

<210> 12

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 12

gcaaacaatg ggcgaacgac cggcactgac aaccttat

38

<210> 13

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 13

ggctttggac gcttgttta aacacgagct ctccc

35

<210> 14

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 14

taaaacaagc gtccaaagcc ttatactggg tgc

33

<210> 15

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 15

actgctaggc tccctcttgc tgaccat

27

<210> 16

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 16

agtataaggc tttggacgct tgttttaaac acgag 35

<210> 17  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 17  
gtcagtgccg gtcgtagcc cattgtttgc ggccac 36

<210> 18  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 18  
agcttaccca catcatatg 19

<210> 19  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 19  
tcaactgctgt cacatgt 17

<210> 20  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 20  
gccgatgatt accaattctc 20

<210> 21  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 21  
acccagccaa tcacatc 17

<210> 22

<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 22

cggagtactt catgga

16

<210> 23

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 23

ggaagacgcc atgaca

16

<210> 24

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 24

ctatggcgag attgagaa

18

<210> 25

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 25

atggccaact tcgcact

17

<210> 26

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 26

caagattctg cagccac

17

<210> 27

<211> 17

<212> DNA

<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 27  
caggagtact tcccaaa 17

<210> 28  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 28  
aacctcaagt catcaagtg 19

<210> 29  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 29  
tcacttagca tgctgag 17

<210> 30  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 30  
gtcactctac aagttcaac 19

<210> 31  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 31  
gtctgtgggt tcttaac 17

<210> 32  
<211> 1012  
<212> PRT  
<213> Infectious bursal disease virus

<400> 32

Met Thr Asn Leu Gln Asp Gln Thr Gln Gln Ile Val Pro Phe Ile Arg  
 1 5 10 15  
 Ser Leu Leu Met Pro Thr Thr Gly Pro Ala Ser Ile Pro Asp Asp Thr  
 20 25 30  
 Leu Glu Lys His Thr Leu Arg Ser Glu Thr Ser Thr Tyr Asn Leu Thr  
 35 40 45  
 Val Gly Asp Thr Gly Ser Gly Leu Ile Val Phe Phe Pro Gly Phe Pro  
 50 55 60  
 Gly Ser Ile Val Gly Ala His Tyr Thr Leu Gln Ser Asn Gly Asn Tyr  
 65 70 75 80  
 Lys Phe Asp Gln Met Leu Leu Thr Ala Gln Asn Leu Pro Ala Ser Tyr  
 85 90 95  
 Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Thr Val Arg Ser Ser Thr  
 100 105 110  
 Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Thr Ile Asn Ala Val Thr  
 115 120 125  
 Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Val Ser Tyr Asn Gly Leu  
 130 135 140  
 Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Ile Gly Asn Val Leu Val  
 145 150 155 160  
 Gly Glu Gly Val Thr Val Leu Ser Leu Pro Thr Ser Tyr Asp Leu Gly  
 165 170 175  
 Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Ile Gly Leu Asp Pro Lys  
 180 185 190  
 Met Val Ala Thr Cys Asp Ser Ser Asp Arg Pro Arg Val Tyr Thr Ile  
 195 200 205  
 Thr Ala Ala Asp Asp Tyr Gln Phe Ser Ser Gln Tyr Gln Ala Gly Gly  
 210 215 220  
 Val Thr Ile Thr Leu Phe Ser Ala Asn Ile Asp Ala Ile Thr Ser Leu  
 225 230 235 240  
 Ser Ile Gly Gly Glu Leu Val Phe Gln Thr Ser Val Gln Gly Leu Ile  
 245 250 255  
 Leu Gly Ala Thr Ile Tyr Leu Ile Gly Phe Asp Gly Thr Ala Val Ile  
 260 265 270  
 Thr Arg Ala Val Ala Ala Asp Asn Gly Leu Thr Ala Gly Thr Asp Asn  
 275 280 285  
 Leu Met Pro Phe Asn Ile Val Ile Pro Thr Ser Glu Ile Thr Gln Pro  
 290 295 300

Ile Thr Ser Ile Lys Leu Glu Ile Val Thr Ser Lys Ser Gly Gly Gln  
 305 310 315 320  
 Ala Gly Asp Gln Met Ser Trp Ser Ala Ser Gly Ser Leu Ala Val Thr  
 325 330 335  
 Ile His Gly Gly Asn Tyr Pro Gly Ala Leu Arg Pro Val Thr Leu Val  
 340 345 350  
 Ala Tyr Glu Arg Val Ala Thr Gly Ser Val Val Thr Val Ala Gly Val  
 355 360 365  
 Ser Asn Phe Glu Leu Ile Pro Asn Pro Glu Leu Ala Lys Asn Leu Val  
 370 375 380  
 Thr Glu Tyr Gly Arg Phe Asp Pro Gly Ala Met Asn Tyr Thr Lys Leu  
 385 390 395 400  
 Ile Leu Ser Glu Arg Asp Arg Leu Gly Ile Lys Thr Val Trp Pro Thr  
 405 410 415  
 Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Met Glu Val Ala Asp Leu  
 420 425 430  
 Asn Ser Pro Leu Lys Ile Ala Gly Ala Phe Gly Phe Lys Asp Ile Ile  
 435 440 445  
 Arg Ala Leu Arg Arg Ile Ala Val Pro Val Val Ser Thr Leu Phe Pro  
 450 455 460  
 Pro Ala Ala Pro Leu Ala His Ala Ile Gly Glu Gly Val Asp Tyr Leu  
 465 470 475 480  
 Leu Gly Asp Glu Thr Gln Ala Ala Ser Gly Thr Ala Arg Ala Ala Ser  
 485 490 495  
 Gly Lys Ala Arg Ala Ala Ser Gly Arg Ile Arg Gln Leu Thr Leu Ala  
 500 505 510  
 Ala Asp Lys Gly Tyr Glu Val Val Ala Asn Leu Phe Gln Val Pro Gln  
 515 520 525  
 Asn Pro Val Val Asp Gly Ile Leu Ala Ser Pro Gly Ile Leu Arg Gly  
 530 535 540  
 Ala His Asn Leu Asp Cys Val Leu Arg Glu Gly Ala Thr Leu Phe Pro  
 545 550 555 560  
 Val Val Ile Thr Thr Val Glu Asp Ala Met Thr Pro Lys Ala Leu Asn  
 565 570 575  
 Ser Lys Met Phe Ala Val Ile Glu Gly Val Arg Glu Asp Leu Gln Pro  
 580 585 590  
 Pro Ser Gln Arg Gly Ser Phe Ile Arg Thr Leu Ser Gly His Arg Val  
 595 600 605



Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pro Leu Glu Thr Gly Arg Asp  
 610 615 620  
 Tyr Thr Val Val Pro Ile Asp Asp Val Trp Asp Asp Ser Ile Met Leu  
 625 630 635 640  
 Ser Lys Asp Pro Ile Pro Pro Ile Val Gly Asn Ser Gly Thr Leu Ala  
 645 650 655  
 Ile Ala Tyr Met Asp Val Phe Arg Pro Lys Val Pro Ile His Val Ala  
 660 665 670  
 Met Thr Gly Ala Leu Asn Ala Tyr Gly Glu Ile Glu Asn Val Ser Phe  
 675 680 685  
 Arg Ser Thr Lys Leu Ala Thr Ala His Arg Leu Gly Leu Lys Leu Ala  
 690 695 700  
 Gly Pro Gly Ala Phe Asp Val Asn Thr Gly Ser Asn Trp Ala Thr Phe  
 705 710 715 720  
 Ile Lys Arg Phe Pro His Asn Pro Arg Asp Trp Asp Arg Leu Pro Tyr  
 725 730 735  
 Leu Asn Leu Pro Tyr Leu Pro Pro Asn Ala Gly Arg Gln Tyr Asp Leu  
 740 745 750  
 Ala Met Ala Ala Ser Glu Phe Lys Glu Thr Pro Glu Leu Glu Ser Ala  
 755 760 765  
 Val Arg Ala Met Glu Ala Ala Ala Asn Val Asp Pro Leu Phe Gln Ser  
 770 775 780  
 Ala Leu Ser Val Phe Met Trp Leu Glu Glu Asn Gly Ile Val Thr Asp  
 785 790 795 800  
 Met Ala Asn Phe Ala Leu Ser Asp Pro Asn Ala His Arg Met Arg Asn  
 805 810 815  
 Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Lys Ser Gln Arg Ala Lys  
 820 825 830  
 Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Arg Gly Pro Thr Pro Glu  
 835 840 845  
 Glu Ala Gln Arg Glu Lys Asp Thr Arg Ile Ser Lys Lys Met Glu Thr  
 850 855 860  
 Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Val Ala Leu Asn Gly His  
 865 870 875 880  
 Arg Gly Pro Ser Pro Gly Gln Leu Lys Tyr Trp Gln Asn Thr Arg Glu  
 885 890 895  
 Ile Pro Asp Pro Asn Glu Asp Tyr Leu Asp Tyr Val His Ala Glu Lys  
 900 905 910

Ser Arg Leu Ala Ser Glu Glu Gln Ile Leu Arg Ala Ala Thr Ser Ile  
 915 920 925

Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gln Ala Phe Ile Asp Glu  
 930 935 940

Val Ala Lys Val Tyr Glu Ile Asn His Gly Arg Gly Pro Asn Gln Glu  
 945 950 955 960

Gln Met Lys Asp Leu Leu Leu Thr Ala Met Glu Met Lys His Arg Asn  
 965 970 975

Pro Arg Arg Ala Pro Pro Lys Pro Lys Pro Lys Pro Asn Val Pro Thr  
 980 985 990

Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Ile Arg Ala Val Ser Asp  
 995 1000 1005

Glu Asp Leu Glu  
 1010

<210> 33  
 <211> 879  
 <212> PRT  
 <213> Infectious bursal disease virus

<400> 33  
 Met Ser Asp Val Phe Asn Ser Pro Gln Ala Arg Ser Lys Ile Ser Ala  
 1 5 10 15

Ala Phe Gly Ile Lys Pro Thr Val Gly Gln Asp Val Glu Glu Leu Leu  
 20 25 30

Ile Pro Lys Val Trp Val Pro Pro Glu Asp Pro Leu Ala Ser Pro Ser  
 35 40 45

Arg Leu Ala Lys Phe Leu Arg Glu Asn Gly Tyr Lys Ile Leu Gln Pro  
 50 55 60

Arg Ser Leu Pro Glu Asn Glu Glu Tyr Glu Thr Asp Gln Ile Leu Pro  
 65 70 75 80

Asp Leu Ala Trp Met Arg Gln Ile Glu Gly Ala Val Leu Lys Pro Thr  
 85 90 95

Leu Ser Leu Pro Ile Gly Asp Gln Glu Tyr Phe Pro Lys Tyr Tyr Pro  
 100 105 110

Thr His Arg Pro Ser Lys Glu Lys Pro Asn Ala Tyr Pro Pro Asp Ile  
 115 120 125

Ala Leu Leu Lys Gln Met Ile Tyr Leu Phe Leu Gln Val Pro Glu Ala  
 130 135 140

Thr Asp Asn Leu Lys Asp Glu Val Thr Leu Leu Thr Gln Asn Ile Arg  
 145 150 155 160

Asp Lys Ala Tyr Gly Ser Gly Thr Tyr Met Gly Gln Ala Thr Arg Leu  
 165 170 175  
 Val Ala Met Lys Glu Val Ala Thr Gly Arg Asn Pro Asn Lys Asp Pro  
 180 185 190  
 Leu Lys Leu Gly Tyr Thr Phe Glu Ser Ile Ala Gln Leu Leu Asp Ile  
 195 200 205  
 Thr Leu Pro Val Gly Pro Pro Gly Glu Asp Asp Lys Pro Trp Val Pro  
 210 215 220  
 Leu Thr Arg Val Pro Ser Arg Met Leu Val Leu Thr Gly Asp Val Asp  
 225 230 235 240  
 Gly Glu Phe Glu Val Glu Asp Tyr Leu Pro Lys Ile Asn Leu Lys Ser  
 245 250 255  
 Ser Ser Gly Leu Pro Tyr Val Gly Arg Thr Lys Gly Glu Thr Ile Gly  
 260 265 270  
 Glu Met Ile Ala Ile Ser Asn Gln Phe Leu Arg Glu Leu Ser Ala Leu  
 275 280 285  
 Leu Lys Gln Gly Ala Gly Thr Lys Gly Ser Asn Lys Lys Lys Leu Leu  
 290 295 300  
 Ser Met Leu Ser Asp Tyr Trp Tyr Leu Ser Cys Gly Leu Leu Phe Pro  
 305 310 315 320  
 Lys Ala Glu Arg Tyr Asp Lys Ser Thr Trp Leu Thr Lys Thr Arg Asn  
 325 330 335  
 Ile Trp Ser Ala Pro Ser Pro Thr His Leu Met Ile Ser Met Ile Thr  
 340 345 350  
 Trp Pro Val Met Ser Asn Ser Pro Asn Asn Val Leu Asn Ile Glu Gly  
 355 360 365  
 Cys Pro Ser Leu Tyr Lys Phe Asn Pro Phe Arg Gly Gly Leu Asn Arg  
 370 375 380  
 Ile Val Glu Trp Ile Met Ala Pro Asp Glu Pro Lys Ala Leu Val Tyr  
 385 390 395 400  
 Ala Asp Asn Ile Tyr Ile Val His Ser Asn Thr Trp Tyr Ser Ile Asp  
 405 410 415  
 Leu Glu Lys Gly Glu Ala Asn Cys Thr Arg Gln His Met Gln Ala Ala  
 420 425 430  
 Met Tyr Tyr Ile Leu Thr Arg Gly Trp Ser Asp Asn Gly Asp Pro Met  
 435 440 445  
 Phe Asn Gln Thr Trp Ala Thr Phe Ala Met Asn Ile Ala Pro Ala Leu  
 450 455 460

Val Val Asp Ser Ser Cys Leu Ile Met Asn Leu Gln Ile Lys Thr Tyr  
 465 470 475 480  
 Gly Gln Gly Ser Gly Asn Ala Ala Thr Phe Ile Asn Asn His Leu Leu  
 485 490 495  
 Gly Thr Leu Val Leu Asp Gln Trp Asn Leu Met Lys Gln Pro Ser Pro  
 500 505 510  
 Asp Ser Glu Glu Phe Lys Ser Ile Glu Asp Lys Leu Gly Ile Asn Phe  
 515 520 525  
 Lys Ile Glu Arg Ser Ile Asp Asp Ile Arg Gly Lys Leu Arg Gln Leu  
 530 535 540  
 Val Pro Leu Ala Gln Pro Gly Tyr Leu Ser Gly Gly Val Glu Pro Glu  
 545 550 555 560  
 Gln Pro Ser Pro Thr Val Glu Leu Asp Leu Leu Gly Trp Ser Ala Thr  
 565 570 575  
 Tyr Ser Lys Asp Leu Gly Ile Tyr Val Pro Val Leu Asp Lys Glu Arg  
 580 585 590  
 Leu Phe Cys Ser Ala Ala Tyr Pro Lys Gly Val Glu Asn Lys Ser Leu  
 595 600 605  
 Lys Ser Lys Val Gly Ile Glu Gln Ala Tyr Lys Val Val Arg Tyr Glu  
 610 615 620  
 Ala Leu Arg Leu Val Gly Gly Trp Asn Tyr Pro Leu Leu Asn Lys Ala  
 625 630 635 640  
 Cys Lys Asn Asn Ala Ser Ala Ala Arg Arg His Leu Glu Ala Lys Gly  
 645 650 655  
 Phe Pro Leu Asp Glu Phe Leu Ala Glu Trp Ser Glu Leu Ser Glu Phe  
 660 665 670  
 Gly Glu Ala Phe Glu Gly Phe Asn Ile Lys Leu Thr Val Thr Pro Glu  
 675 680 685  
 Ser Leu Ala Glu Leu Asn Arg Pro Val Pro Pro Lys Pro Pro Asn Val  
 690 695 700  
 Asn Arg Pro Val Asn Thr Gly Gly Leu Lys Ala Val Ser Asn Ala Leu  
 705 710 715 720  
 Lys Thr Gly Arg Tyr Arg Asn Glu Ala Gly Leu Ser Gly Leu Val Leu  
 725 730 735  
 Leu Ala Thr Ala Arg Ser Arg Leu Gln Asp Ala Val Lys Ala Lys Ala  
 740 745 750  
 Glu Ala Glu Lys Leu His Lys Ser Lys Pro Asp Asp Pro Asp Ala Asp  
 755 760 765

Trp Phe Glu Arg Ser Glu Thr Leu Ser Asp Leu Leu Glu Lys Ala Asp  
 770 775 780

Ile Ala Ser Lys Val Ala His Ser Ala Leu Val Glu Thr Ser Asp Ala  
 785 790 795 800

Leu Glu Ala Val Gln Ser Thr Ser Val Tyr Thr Pro Lys Tyr Pro Glu  
 805 810 815

Val Lys Asn Pro Gln Thr Ala Ser Asn Pro Val Val Gly Leu His Leu  
 820 825 830

Pro Ala Lys Arg Ala Thr Gly Val Gln Ala Ala Leu Leu Gly Ala Gly  
 835 840 845

Thr Ser Arg Pro Met Gly Met Glu Ala Pro Thr Arg Ser Lys Asn Ala  
 850 855 860

- Val Lys Met Ala Lys Arg Arg Gln Arg Gln Lys Glu Ser Arg Gln  
 865 870 875



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 7 :</b> <b>C12N 15/00, 15/10, C07K 13/00, A61K 39/15</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/12677</b> <b>(43) International Publication Date:</b> 9 March 2000 (09.03.00)																																																									
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <b>(21) International Application Number:</b> PCT/IB99/01604  <b>(22) International Filing Date:</b> 1 September 1999 (01.09.99)   <b>(30) Priority Data:</b>          60/098,684      1 September 1998 (01.09.98)      US   <b>(71) Applicant:</b> THE UNIVERSITY OF HONG KONG [CN/CN];          G18, Eliot Hall, Pokfulam Road, Hong Kong (CN).   <b>(72) Inventor:</b> LIM, Boon-Leong; Tower I, 39th floor, Flat E,          Kornville Garden, 38 Yau Man Street, Hong Kong (CN).   <b>(74) Agent:</b> CHINA PATENT AGENT (H.K.) LTD.; 22/F, Great          Eagle Centre, 23 Harbour Road, Wanchai, Special Admin-          istrative Region Hong Kong (CN).       </div> <div style="width: 48%;"> <b>(81) Designated States:</b> European patent (AT, BE, CH, CY, DE,          DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).   <b>Published</b>  <i>With international search report.</i>   <b>(88) Date of publication of the international search report:</b>          29 June 2000 (29.06.00)       </div> </div>																																																											
<b>(54) Title:</b> GENERATION OF RECOMBINANT INFECTIOUS BURSAL DISEASE VIRUSES BY REVERSE GENETICS TECHNOLOGY AND THE USE OF THE RECOMBINANT VIRUSES AS ATTENUATED VACCINES																																																											
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%; text-align: right;">143</td> <td style="width: 65%;"></td> <td style="width: 20%; text-align: right;">222</td> </tr> <tr> <td style="text-align: right;">HK46</td> <td>.....</td> <td style="text-align: right;">A</td> </tr> <tr> <td style="text-align: right;">UK661</td> <td>.....</td> <td style="text-align: right;">A</td> </tr> <tr> <td style="text-align: right;">G9201</td> <td>.....</td> <td style="text-align: right;">A</td> </tr> <tr> <td style="text-align: right;">F9502</td> <td>.....</td> <td style="text-align: right;">A</td> </tr> <tr> <td style="text-align: right;">G9303</td> <td>.....A.....</td> <td style="text-align: right;">V...A...A</td> </tr> <tr> <td style="text-align: right;">52/70</td> <td>.....</td> <td style="text-align: right;">.....</td> </tr> <tr> <td style="text-align: right;">STC</td> <td>.....</td> <td style="text-align: right;">.....</td> </tr> <tr> <td style="text-align: right;">CJ801</td> <td>.....S.....</td> <td style="text-align: right;">.....L...T</td> </tr> <tr> <td style="text-align: right;">Variant-A</td> <td>.....</td> <td style="text-align: right;">.....Q</td> </tr> <tr> <td style="text-align: right;">Variant-E</td> <td>.....</td> <td style="text-align: right;">N.....T</td> </tr> <tr> <td style="text-align: right;">G2902</td> <td>.....</td> <td style="text-align: right;">.....Q</td> </tr> <tr> <td style="text-align: right;">GLS</td> <td>.....</td> <td style="text-align: right;">.....T</td> </tr> <tr> <td style="text-align: right;">CJ801BKF</td> <td>.....</td> <td style="text-align: right;">.....</td> </tr> <tr> <td style="text-align: right;">CU-1</td> <td>.....</td> <td style="text-align: right;">.....</td> </tr> <tr> <td style="text-align: right;">PBG-98</td> <td>.....</td> <td style="text-align: right;">.....</td> </tr> <tr> <td style="text-align: right;">G2911</td> <td>.....</td> <td style="text-align: right;">.....</td> </tr> <tr> <td style="text-align: right;">002-73</td> <td>.....</td> <td style="text-align: right;">G</td> </tr> <tr> <td style="text-align: right;">Consensus</td> <td>GLMSATANIN DKIGNVLGE GVTVLSLPTS YDLGYVRLGD PIPAIGLDPK MWATCOSSDR PRVYTITAA</td> <td style="text-align: right;">D DYQFSSQYCP</td> </tr> </table>			143		222	HK46	.....	A	UK661	.....	A	G9201	.....	A	F9502	.....	A	G9303	.....A.....	V...A...A	52/70	.....	.....	STC	.....	.....	CJ801	.....S.....	.....L...T	Variant-A	.....	.....Q	Variant-E	.....	N.....T	G2902	.....	.....Q	GLS	.....	.....T	CJ801BKF	.....	.....	CU-1	.....	.....	PBG-98	.....	.....	G2911	.....	.....	002-73	.....	G	Consensus	GLMSATANIN DKIGNVLGE GVTVLSLPTS YDLGYVRLGD PIPAIGLDPK MWATCOSSDR PRVYTITAA	D DYQFSSQYCP
143		222																																																									
HK46	.....	A																																																									
UK661	.....	A																																																									
G9201	.....	A																																																									
F9502	.....	A																																																									
G9303	.....A.....	V...A...A																																																									
52/70	.....	.....																																																									
STC	.....	.....																																																									
CJ801	.....S.....	.....L...T																																																									
Variant-A	.....	.....Q																																																									
Variant-E	.....	N.....T																																																									
G2902	.....	.....Q																																																									
GLS	.....	.....T																																																									
CJ801BKF	.....	.....																																																									
CU-1	.....	.....																																																									
PBG-98	.....	.....																																																									
G2911	.....	.....																																																									
002-73	.....	G																																																									
Consensus	GLMSATANIN DKIGNVLGE GVTVLSLPTS YDLGYVRLGD PIPAIGLDPK MWATCOSSDR PRVYTITAA	D DYQFSSQYCP																																																									
<b>(57) Abstract</b>  <p>The invention relates to the generation and mutagenesis of recombinant infectious bursal disease virus by reverse genetics technology. Site-directed mutagenesis of certain amino acid residues on the Non-CEF adapted, very virulent strains of IBDV transforms the viruses into attenuated, CEF-adapted strains. The attenuated, CEF-adapted strains can be used as live vaccines against the very virulent strains. Currently available live attenuated vaccines were generated by serial passage through cell culture and the like, whereas the present invention provides a novel molecular mechanism in manipulation of the viral genome and the generation of attenuated vaccines by site-directed mutagenesis. The same approach can be used to produce vaccine strains from newly evolved IBDV viruses or to manipulate the antigenicity and pathogenicity of the virus.</p>																																																											

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB99/01604

## A. CLASSIFICATION OF SUBJECT MATTER

IPC<sup>7</sup> C12N15/00, C12N15/10, C07K13/00, A61K39/15

According to International Patent Classification(IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched(classification system followed by classification symbols)

IPC<sup>7</sup> C12N15/00, C12N15/10, C07K13/00, A61K39/15

Documentation searched other than minimum documentation to the extent that such documents are included in the field searched

Chinese Patnets, Chinese Scientific and Technical Journals

Electronic data base consulted during the international search(name of data base and, where practicable, search terms-used)

GenBank, EMBL, DDBJ, PDB, SwissProt, Spupdate, PIR, WPI

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant claim No.
X	WO 91/16925 (UNIVERSITY OF MARYLAND AT COLLEGE PARK) 14 November 1991, see whole document	1-24
Y	WO 86/07060 (COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION) 4 December 1986, see whole document	1-24
Y	WO 98/09646 (UNIVERSITY OF MARYLAND - BIOTECHNOLOGY INSTITUTE) 12 March 1998, see whole document	1-24
A	WO 95/26196 (UNIVERSITY OF MARYLAND COLLEGE PARK) 5 October 1995, see whole document	1-24

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:	"F" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason(s) as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

28 February 2000 (28. 02. 2000)

Date of mailing of the international search report

16 MARCH 2000 (16.03.00)

Name and mailing address of the ISA/


The Chinese Patent Office  
6. Xitucheng Road, Haidian District,  
Beijing, 100088, China

Authorized officer

SUN, guangxiu

Facsimile No. 86-010-62019451

Telephone No. 86-010-62093884





**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
**PCT/IB99/01604**

Patent document cited in search report	Publication date	Patent family members	Publication date
WO 91/16925	14-11-91	US 5595912	21-01-97
		EP 0481072	22-04-92
WO 86/07060	04-12-86	EP 0222842	27-05-87
		AU 5966886	24-12-86
		JP 9316094	09-12-97
WO 98/09646	12-03-98	AU 3891897	26-03-98
WO 95/26196	05-10-95	AU 2129195	17-10-95
		JP 9510873	04-11-97
		US 5788970	04-08-98

**THIS PAGE BLANK (USPTO)**